You should contact Stripe. My understanding is that the fee is precisely only for converting currency. Since this is not happening in your case it should not apply.
This looks great! I am curious about "We expect to monetize in the future by building extra features that serve large companies with complex needs".
During the YC application process, was this enough to be accepted? I wonder how much emphasis they put in the business model in order to fund you. I wish you success!
Candidly, we were working on other projects when accepted to YC. We wanted to build data cleaning software with LLMs, before we realized no one really cared about messy data.
Part of the reason we're comfortable with a generous free offering is the basic truth that helping SaaS companies support SAML logins ... just isn't an enormous market. We need to make money on other products anyway.
*Monetizing extra features* pertains to the SAML product that we offer now, but we'll also roll out other products.
The long-term ambition here is that we build a company resembling Auth0, but open source and more developer-friendly.
> We wanted to build data cleaning software with LLMs, before we realized no one really cared about messy data.
This sounds like a good problem to solve with LLMs, and honestly I'm a bit surprised to hear that nobody cared about data being of poor quality. Care to elaborate a little bit?
I should have been a little more careful in my phrasing. Certainly some number of people care about data quality. The motivation for the project came from my own personal experience -- it was a product that I really wanted.
Our positioning (e.g. principal use cases, target verticals, target persona) and timing were totally wrong. We tried to run top-down sales against relatively important data (e.g. sales forecasts). People often expressed an attitudinal interest in the product, but it was very hard to motivate people actually to use the product seriously. Category creation and behavior change are really hard.
If I were trying to sell an LLM data cleaning product now, I'd focus on more technical buyers, someone more like a data engineer than a strong spreadsheet worker. And I'd try to drive bottoms-up, low ACV adoption first.
Doing the post-mortem justice would probably require a long blog post.
> The long-term ambition here is that we build a company resembling Auth0, but open source and more developer-friendly.
I have been working on this for a few years at github.com/authgear, and last few weeks were busy rolling out SAML support for a few Enterprise customers want it by Sep…
We tried about 9 years ago :) we even open sourced the solution. At the time we felt there was not a big enough market so we decided to make it open for anyone to build upon our research.
Happy user of dstack.ai. The simplicity of just spinning up a machine with my required set of GPUs and memory, from my vendor of choice, and have an endpoint to easily access it via ssh and VSCode has been game changing for me.
I once had some trouble setting it up and the founder literally went on a zoom chat with me to help navigate through things. Couldnt recommend them enough!!
This is truly an amazing write-up, thank you!! I would love it if someone with experience in the bio lab scene (PCR machines, electrophoresis, western blot, pipettes, cell incubator, and so on) could write something similar.
The treatment works on the child without symptoms because in most cases neurological affections are irreversible. Since the child had not developed them, the therapy would essentially fix the body before it caused them.
In the case of the child who already shows neurological symptoms, the treatment can help stop the progression of the disease, but most likely not reverse the already existing damage. However, there are already treatments approved to help stop the progression of the disease, including enzyme replacement therapy (provide the enzyme in charge of degrading the sustrate through the bloodstream every so often).
Some would argue that if treatments with similar outcomes already exist and are approved, it could be unethical to test this experimental treatment on a patient (I disagree).
It works surprisingly well for designing UIs using AI
reply